Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival

Journal of Thoracic Oncology

Volumn 2, Issue 8, 2007, Pages 735-740

  Sirohi, Bhawna ^a   Ashley, Sue ^a   Norton, Alison ^a   Popat, Sanjay ^a   Hughes, Sarah ^a   Papadopoulos, Panagiotous ^a   Priest, Kathryn ^a   O'Brien, Mary ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Early response; Non small cell

Indexed keywords

CARBOPLATIN; CHROMIUM 51; CISPLATIN; DOCETAXEL; EDETIC ACID; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM; VINBLASTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PALLIATIVE THERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34548396706     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31811f3a7d     Document Type: Article

References (19)

1. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3108.
3. Shepherd FA. Chemotherapy for non small cell lung cancer: have we reached a new plateau? Semin Oncol 1999;26:3-11.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med 2002;346:92-98.
5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non small cell lung cancer: the TAX 326 Study Group J Clin Oncol 2003;21:3016-3024.
6. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006;17:1111-1119.
7. Smith IE O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 2001;19:1336-1343.
8. Socinksi M, Kies M, Schell M, et al. Duration of therapy in stage IIIB/IV non small cell lung cancer (NSCLC): a multi-institutional phase III trial (Abstract 1232). Proc Am Soc Clin Oncol 2001;20:309a
9. Piedbois P Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004;22:3839-3841.
10. Sculier J, Lafitte J, Lecomte J, et al. A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) (Abstract 7012). J Clin Oncol 2006;24:367s.
11. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
12. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
13. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1976;35:1-39.
14. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989.
15. Fidias P, Dakhil SR, Lyss AP, et al. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs immediate second line therapy with docetaxel (D) in advanced non small cell lung cancer (NSCLC) (Abstract 7032). J Clin Oncol 2006;24.
16. Victorson D, Soni M, Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 2006;106:494-504.
17. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
18. Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide excision repair pathways involved in cisplatin resistance in non small cell lung cancer. Cancer Control 2003;10:297-305.
19. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-8370.